Investigating histidine phosphorylation as a new target for cancer treatment
Histidine phosphorylation as a new target for cancer therapy
This study is looking at a special change in proteins that could help us find new ways to treat liver cancer by using special tools to see how this change affects cancer cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-10893641 on NIH RePORTER |
What this research studies
This research focuses on understanding how histidine phosphorylation in proteins can be targeted for cancer therapy. The team has developed specialized antibodies to detect and analyze this modification in proteins, which is crucial for cellular signaling. By studying the presence of phosphorylated histidine in cancer cells, particularly in hepatocellular carcinoma, the researchers aim to uncover new therapeutic targets and mechanisms of action. This approach could lead to innovative treatments that specifically address the underlying signaling pathways involved in cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma or other cancers where histidine phosphorylation plays a role.
Not a fit: Patients with cancers unrelated to histidine phosphorylation or those who do not have hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new cancer therapies that specifically target the mechanisms of histidine phosphorylation.
How similar studies have performed: While the specific targeting of histidine phosphorylation is a novel approach, related research has shown promise in understanding protein modifications in cancer.
Where this research is happening
La Jolla, UNITED STATES
- Salk Institute for Biological Studies — La Jolla, United States (Active)
Researchers
- Principal investigator: Hunter, Tony R. — Salk Institute for Biological Studies
- Study coordinator: Hunter, Tony R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.